External validation of the fullPIERS model for predicting adverse maternal outcomes in pregnancy hypertension in low- and middle-income countries demonstrated increasing numbers of events according to the progressive increase in prediction score, with a 16.6% risk of adverse events when the prediction score was ≥0.1 (or 10%).11 A second available method uses the biomarker sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio as a prognostic marker for maternal adverse outcomes and has the potential to identify patients who do not need a delivery. Here, PGF is linked to hypertension, pregnancy-induced.